BACKGROUND/AIMS: The outcome of acute hepatitis B infection may be influenced by host factors like the major histocompatibility complex (MHC). We have investigated MHC class I and class II antigens in patients with chronic hepatitis B compared to a healthy control population. To confirm the findings of this first study we performed a second study in a group of subjects who had spontaneously recovered from acute hepatitis B infection. METHODS: Frequencies of MHC class I and class II antigens were analyzed in patients with chronic hepatitis B virus infection and in control subjects. MHC class I typing was done by standard microlymphocytotoxicity assays. DRB1 and DQA1 genotypes were determined by polymerase chain reaction based typing methods. RESULTS: In the first study the class II allele HLA-DRB1*1301-02 was found in 4 of 70 subjects with chronic hepatitis B virus infection (5.7%) compared to 27 of 101 healthy controls (26.7%, relative risk 0.17; p=0.001; p(corr)=0.025). This protective effect of the DRB1*1301-02 allele was confirmed in the second study. Eight of 24 patients (33.3%) who cleared hepatitis B virus spontaneously were positive for DRB1*1301-02 (relative risk of developing chronic infection compared to chronic hepatitis B subjects 0.12; p=0.004). Subtyping confirmed that 1301 and 1302 were both decreased in frequency in patients with chronic hepatitis B. CONCLUSIONS: The MHC class II allele DRB1* 1301-02 is associated with protection from chronic hepatitis B in Caucasian patients.
BACKGROUND/AIMS: The outcome of acute hepatitis B infection may be influenced by host factors like the major histocompatibility complex (MHC). We have investigated MHC class I and class II antigens in patients with chronic hepatitis B compared to a healthy control population. To confirm the findings of this first study we performed a second study in a group of subjects who had spontaneously recovered from acute hepatitis B infection. METHODS: Frequencies of MHC class I and class II antigens were analyzed in patients with chronic hepatitis B virus infection and in control subjects. MHC class I typing was done by standard microlymphocytotoxicity assays. DRB1 and DQA1 genotypes were determined by polymerase chain reaction based typing methods. RESULTS: In the first study the class II allele HLA-DRB1*1301-02 was found in 4 of 70 subjects with chronic hepatitis B virus infection (5.7%) compared to 27 of 101 healthy controls (26.7%, relative risk 0.17; p=0.001; p(corr)=0.025). This protective effect of the DRB1*1301-02 allele was confirmed in the second study. Eight of 24 patients (33.3%) who cleared hepatitis B virus spontaneously were positive for DRB1*1301-02 (relative risk of developing chronic infection compared to chronic hepatitis B subjects 0.12; p=0.004). Subtyping confirmed that 1301 and 1302 were both decreased in frequency in patients with chronic hepatitis B. CONCLUSIONS: The MHC class II allele DRB1* 1301-02 is associated with protection from chronic hepatitis B in Caucasian patients.
Authors: H M Diepolder; M C Jung; E Keller; W Schraut; J T Gerlach; N Grüner; R Zachoval; R M Hoffmann; C A Schirren; S Scholz; G R Pape Journal: Clin Exp Immunol Date: 1998-08 Impact factor: 4.330
Authors: Yong Kwang Park; Jung Min Lee; Do Young Kim; Hye Young Chang; Ja Kyung Kim; Chun Kyon Lee; Jun Yong Park; Sang Hoon Ahn; Kwan Sik Lee; Kwang Hyub Han Journal: Dig Dis Sci Date: 2009-10-15 Impact factor: 3.199
Authors: Jae Youn Cheong; Sung Won Cho; Sun Kyo Lim; Do Hyun Shin; Seung Kew Yoon; Jong Eun Lee; Ki Baik Hahm; Jin Hong Kim Journal: J Korean Med Sci Date: 2005-02 Impact factor: 2.153